In the early NOAH study, a combination of chemotherapy and trastuzumab demonstrated a substantial 21% increase in the pathological complete response (pCR) rate, providing a crucial foundation for neoadjuvant treatment in HER2-positive breast cancer (4). This evidence concerns the gene ERBB2 and breast cancer.